Atomoxetine for children with acquired attentional disorders following completion of chemotherapy for acute lymphocytic leukemia

Trial Profile

Atomoxetine for children with acquired attentional disorders following completion of chemotherapy for acute lymphocytic leukemia

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 25 Apr 2012

At a glance

  • Drugs Atomoxetine (Primary)
  • Indications Attention-deficit hyperactivity disorder
  • Focus Therapeutic Use
  • Most Recent Events

    • 25 Apr 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
    • 25 Apr 2012 Actual patient number is 1 according to ClinicalTrials.gov.
    • 14 Nov 2006 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top